Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2370645rdf:typepubmed:Citationlld:pubmed
pubmed-article:2370645lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2370645lifeskim:mentionsumls-concept:C0341697lld:lifeskim
pubmed-article:2370645lifeskim:mentionsumls-concept:C0012368lld:lifeskim
pubmed-article:2370645pubmed:dateCreated1990-8-17lld:pubmed
pubmed-article:2370645pubmed:abstractTextDilevalol, 200 mg, was administered orally as seven daily doses to three groups of six participants, with differing degrees of renal impairment. Values of Cmax, Tmax, half-life or renal elimination did not significantly change with decreased renal function. Values of area under the plasma concentration-time curves and pre-dose concentrations tended to increase with renal impairment and there was a significant, if small, correlation between these and glomerular filtration rate. The practical clinical consequences of these results is that impairment is not likely to be associated with significant accumulation of dilevalol.lld:pubmed
pubmed-article:2370645pubmed:languageenglld:pubmed
pubmed-article:2370645pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2370645pubmed:citationSubsetIMlld:pubmed
pubmed-article:2370645pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2370645pubmed:statusMEDLINElld:pubmed
pubmed-article:2370645pubmed:monthJunlld:pubmed
pubmed-article:2370645pubmed:issn0950-9240lld:pubmed
pubmed-article:2370645pubmed:authorpubmed-author:KellyJ GJGlld:pubmed
pubmed-article:2370645pubmed:authorpubmed-author:DoyleG DGDlld:pubmed
pubmed-article:2370645pubmed:authorpubmed-author:DonohueJJlld:pubmed
pubmed-article:2370645pubmed:authorpubmed-author:LaherM SMSlld:pubmed
pubmed-article:2370645pubmed:issnTypePrintlld:pubmed
pubmed-article:2370645pubmed:volume4 Suppl 2lld:pubmed
pubmed-article:2370645pubmed:ownerNLMlld:pubmed
pubmed-article:2370645pubmed:authorsCompleteYlld:pubmed
pubmed-article:2370645pubmed:pagination59-62lld:pubmed
pubmed-article:2370645pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:meshHeadingpubmed-meshheading:2370645-...lld:pubmed
pubmed-article:2370645pubmed:year1990lld:pubmed
pubmed-article:2370645pubmed:articleTitleThe pharmacokinetics of dilevalol in renal impairment.lld:pubmed
pubmed-article:2370645pubmed:affiliationInstitute of Biopharmaceuticals, Athlone, Ireland.lld:pubmed
pubmed-article:2370645pubmed:publicationTypeJournal Articlelld:pubmed